Skip to main content
Signal8

MindMaze Therapeutics Holding SA (RLFTY)

MindMaze Therapeutics Holding SA operates as a commercial-stage biopharmaceutical and neurotechnology company in Asia, the United States, Switzerland, rest of Europe, and internationally. The company offers MindPod system, a supervised in-clinic neurorehabilitation system designed to initiate and intensify the recovery journey; MindMotion GO, which extends protocolized neurotherapeutics into outpatient and home settings; MindMotion Companion, an application that manages prescription, monitoring and documentation across MindMaze Therapeutics' neurotherapeutics ecosystem; and the patient app, a patient-facing mobile application, that supports clinic-to-home continuity by making prescribed therapy easy to follow outside the clinic. It also provides Izar hand therapy device which supports fine motor rehabilitation; Physilog sensor, a wearable inertial sensing device designed to quantify human movement; toaprun, a training for Parkinson's therapy-reimagined through play. The company was founded in 2012 and is headquartered in Geneva, Switzerland.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

MindMaze Therapeutics Holding S.A. logo

MindMaze Therapeutics Holding S.A.

CLOSED
Mkt Cap-
EV-
Float37.2M
O/S-
VOL3K sh
$ Vol$445
RVOL1.00×
Inst Own-
SI0.1%
Net Cash/Sh-
Dilution
Pipeline3 lead-sponsored trials·1 active1 completed(5 more as collaborator)

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Sponsor role
Status
  • Not applicable
    Terminated

    Study Evaluating the MindMotionPRO for Early Post-stroke Upper-limb Rehabilitation

    MindMotionPRO, Self-Directed Prescribed Exercises

    Stroke, Motor Disorders

    Enrollment
    9
    Start
    Aug 2016
    Primary Completion
    Aug 2017
    Completion
    Feb 2018
    NCT02688413
  • Not applicable
    Completed

    Immersive Virtual Reality for Stroke Motor Rehabilitation

    MindMotion PRO

    Chronic Stroke, Motor Disorders

    Enrollment
    10
    Start
    Feb 2015
    Primary Completion
    Oct 2015
    Completion
    Nov 2015
    NCT03094650
  • Not applicable
    Recruiting

    Virtual-reality Exercises for Alleviating Attention Deficits in Patients With Acquired Brain Injury

    Immersive virtual reality gamified cognitive activities, Double neuropsychological standard activities

    Stroke, Attention Disorder

    Enrollment
    135
    Start
    Feb 2023
    Primary Completion
    Jul 2026est.
    Completion
    Jul 2026est.
    NCT05728840